Navigation Links
Accuray Showcases CyberKnife Robotic Radiosurgery System at American Urological Association Meeting
Date:5/16/2011

SUNNYVALE, Calif. and WASHINGTON, May 16, 2011 /PRNewswire/ -- The American Urological Association (AUA) Meeting, May 16, 2011 -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that it will showcase the CyberKnife® Robotic Radiosurgery System, used to treat more than 6,500 prostate cancer patients around the world to date, in the company's booth (#3243) at the American Urological Association (AUA) meeting. Accuray will also sponsor a theater presentation on use of the CyberKnife System for prostate cancer, highlighting published long-term data on outcomes and the important role of multidisciplinary teams in treating prostate cancer patients with SBRT.  The AUA meeting takes place May 14-17, 2011 in Washington, D.C.

"Recently published five-year data on CyberKnife SBRT for prostate cancer validates the long-term efficacy of prostate SBRT," said Omar Dawood, vice president, medical affairs, Accuray. "This adds to the growing body of clinical evidence in support of the CyberKnife System for prostate cancer. The unique capabilities of our robotic technology to track and correct for prostate movement has helped Accuray solidify our position as a leader in the field of prostate SBRT. In the first quarter of calendar year 2011, we achieved a 20 percent increase in worldwide prostate cancer treatments as compared to the same period last year and look forward to continued wide adoption of this non surgical treatment option."

On Tuesday, May 17 at 3:00 p.m. E.T., Accuray will host a presentation at the AUA Industry Clinical Update Theatre on "CyberKnife Prostate SBRT Outcomes and Experiences." Lee Ponsky, MD, FACS, director of the Center for Urologic Oncology and Minimally Invasive Therapies at University Hospitals Case Medical Center in Cleveland, and Debra Freeman, MD, senior manager of clinical development at Accuray and oncologist affiliated with Naples Radiation Oncology, will provide an overview of the CyberKnife System and recently published five-year outcomes data on stereotactic body radiotherapy (SBRT) using the CyberKnife System for the treatment of localized, low-risk prostate cancer. The presentation will be followed by a discussion on the role of surgeons as part of a multi-disciplinary team in treating prostate cancer patients with SBRT.

Results of the recently published five-year outcomes on low-risk prostate cancer patients treated with CyberKnife SBRT appeared in the January 10, 2011 issue of Radiation Oncology. The multi-center study, which combined data from 41 patients treated at Stanford University in Stanford, Calif. and Naples Community Hospital in Naples, Fla., showed that 93 percent of patients treated with the CyberKnife System had no recurrence of their cancer at a median follow-up of five years. This rate compares favorably to results obtained with other treatment modalities, including surgery and conventional radiation therapy. In addition, the study demonstrates excellent long term urinary and rectal toxicity results for this short, outpatient five day course of CyberKnife SBRT.

CyberKnife SBRT is a non-invasive treatment option for prostate cancer that can achieve high rates of disease control while sparing critical nearby structures, thereby minimizing undesirable side effects typically associated with other treatment modalities and preserving patients' quality of life. Unlike gantry based systems, the CyberKnife System is the only technology on the market capable of both tracking and automatically correcting for the unpredictable movement of the prostate during treatment. Utilizing its unique robotic platform, the CyberKnife System enables clinicians to deliver highly precise doses of radiation in three dimensions with small treatment margins that minimize radiation doses to critical structures including the rectum, urethra and neurovascular bundles. Additionally, CyberKnife SBRT provides patients a pain-free treatment option that's completed in five or fewer treatment sessions, resulting in minimal interruption to their daily lives.

Attendees interested in participating in the theater presentation may register online.

Media interested in meeting with Accuray at AUA can contact Jenny Ng or Marisa Borgasano at Accuray@schwartzcomm.com  or 781-684-0770.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 226 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical experience and market acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: range of treatment options, clinical applications, and market acceptance of products and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2010 fiscal year, our form 10-Q filed on May 10, 2011 and our other filings with the Securities and Exchange Commission.. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Omar Dawood, M.D., MPH

http://www.profnetconnect.com/omar_dawood_m.d._mph

Euan Thomson, Ph.D.

http://www.profnetconnect.com/euan_thomson_ph.d.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuray Announces Results for Third Quarter of Fiscal 2011
2. Accuray Incorporated Announces HSR Clearance in Acquisition of TomoTherapy
3. Accuray Incorporated to Report Financial Results for Third Quarter of Fiscal 2011
4. Accuray Incorporated to Speak at 10th Annual Needham Healthcare Conference
5. Accuray to Acquire TomoTherapy for Approximately $277 Million in Cash and Stock
6. Accurays General Counsel Wins Best Bay Area Corporate Counsel Award
7. Accuray Announces Results for Second Quarter of Fiscal 2011
8. Accuray Hires Chief Marketing Officer
9. Accuray Elevated to NASDAQ Global Select Market
10. Accuray Incorporateds CEO to Speak at 29th Annual J.P. Morgan Healthcare Conference
11. Accuray Establishes Medical Affairs Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
Breaking Medicine News(10 mins):